ENDRA Life Sciences Faces Delisting Notice
Ticker: NDRA · Form: 8-K · Filed: Jul 17, 2024 · CIK: 1681682
| Field | Detail |
|---|---|
| Company | Endra Life Sciences INC. (NDRA) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2024 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $1.00, $0.10 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
ENDRA's stock is at risk of being delisted.
AI Summary
ENDRA Life Sciences Inc. filed an 8-K on July 17, 2024, reporting a notice of delisting or failure to meet continued listing standards as of July 15, 2024. The company, incorporated in Delaware, is based in Ann Arbor, Michigan, and operates in the electromedical apparatus sector.
Why It Matters
This filing indicates potential issues with ENDRA Life Sciences' ability to remain listed on its current exchange, which could impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to trade on a public exchange, posing a significant risk to investors.
Key Players & Entities
- ENDRA Life Sciences Inc. (company) — Registrant
- July 15, 2024 (date) — Earliest event reported
- July 17, 2024 (date) — Filing date
- Ann Arbor, MI (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What specific listing rule or standard did ENDRA Life Sciences Inc. fail to meet?
The filing does not specify the exact rule or standard that ENDRA Life Sciences Inc. failed to meet, only that it received a notice of delisting or failure to satisfy a continued listing rule or standard.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is July 15, 2024.
When was this 8-K form filed with the SEC?
This 8-K form was filed on July 17, 2024.
Where are ENDRA Life Sciences Inc.'s principal executive offices located?
ENDRA Life Sciences Inc.'s principal executive offices are located at 3600 Green Court, Suite 350, Ann Arbor, MI 48105.
What is ENDRA Life Sciences Inc.'s Standard Industrial Classification (SIC) code?
ENDRA Life Sciences Inc.'s Standard Industrial Classification (SIC) code is 3845, which corresponds to ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS.
Filing Stats: 1,071 words · 4 min read · ~4 pages · Grade level 14 · Accepted 2024-07-17 16:16:45
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share NDRA The Nasdaq Stock Mar
- $1.00 — 's common stock had closed at less than $1.00 per share for 30 consecutive business d
- $0.10 — Company's common stock had closed below $0.10 per share for the 10-consecutive tradin
Filing Documents
- ndra_8k.htm (8-K) — 29KB
- 0001654954-24-009066.txt ( ) — 151KB
- ndra-20240715.xsd (EX-101.SCH) — 6KB
- ndra-20240715_lab.xml (EX-101.LAB) — 14KB
- ndra-20240715_cal.xml (EX-101.CAL) — 1KB
- ndra-20240715_pre.xml (EX-101.PRE) — 9KB
- ndra-20240715_def.xml (EX-101.DEF) — 2KB
- ndra_8k_htm.xml (XML) — 4KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . As previously disclosed, the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notified ENDRA Life Sciences Inc. (the "Company") on May 3, 2024 that the bid price of the Company's common stock had closed at less than $1.00 per share for 30 consecutive business days and, as a result, did not comply with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until October 30, 2024, to regain compliance with the Minimum Bid Price Requirement. On July 15, 2024, the Company received notice from the Staff indicating that the bid price for the Company's common stock had closed below $0.10 per share for the 10-consecutive trading day period ended July 12, 2024 and, accordingly, the Company is subject to the provisions contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii). As a result, the Staff determined to delist the Company's common stock from The Nasdaq Capital Market (the "Delisting Determination"). On July 16, 2024, the Company timely requested a hearing before a Nasdaq Hearings Panel (the "Panel") to appeal the Delisting Determination. The hearing request automatically stays any suspension or delisting action pending the hearing and the expiration of any compliance period granted by the Panel following the hearing. Notwithstanding the Company's request for a hearing, there can be no assurance that the Panel will grant the Company any compliance period or that the Company will ultimately regain compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. The Company is monitoring the closing bid price of its common stock and will consider options to regain compliance with the Minimum Bid Price Requirement, including holding the previously disclosed annual meetin
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENDRA LIFE SCIENCES INC. Date: July 19, 2024 By: /s/ Francois Michelon Name: Francois Michelon Title: President and Chief Executive Officer 3